Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Liabilities and Shareholders Equity (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Liabilities and Shareholders Equity readings, the most recent being $92.1 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 35.11% to $92.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $429.1 million, a 36.69% decrease, with the full-year FY2025 number at $98.2 million, down 38.77% from a year prior.
  • Liabilities and Shareholders Equity hit $92.1 million in Q1 2026 for Barinthus Biotherapeutics, down from $98.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $286.1 million in Q1 2022 to a low of $92.1 million in Q1 2026.
  • Median Liabilities and Shareholders Equity over the past 5 years was $199.5 million (2024), compared with a mean of $198.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 71.85% in 2022 and later crashed 42.13% in 2025.
  • Barinthus Biotherapeutics' Liabilities and Shareholders Equity stood at $270.2 million in 2022, then fell by 20.61% to $214.5 million in 2023, then fell by 25.26% to $160.3 million in 2024, then plummeted by 38.77% to $98.2 million in 2025, then dropped by 6.14% to $92.1 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $92.1 million (Q1 2026), $98.2 million (Q4 2025), and $109.2 million (Q3 2025) per Business Quant data.